198 related articles for article (PubMed ID: 24828094)
1. Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A.
Harris SA; Satti I; Matsumiya M; Stockdale L; Chomka A; Tanner R; O'Shea MK; Manjaly Thomas ZR; Tameris M; Mahomed H; Scriba TJ; Hanekom WA; Fletcher HA; McShane H
Clin Vaccine Immunol; 2014 Jul; 21(7):1005-11. PubMed ID: 24828094
[TBL] [Abstract][Full Text] [Related]
2. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
Scriba TJ; Tameris M; Mansoor N; Smit E; van der Merwe L; Mauff K; Hughes EJ; Moyo S; Brittain N; Lawrie A; Mulenga H; de Kock M; Gelderbloem S; Veldsman A; Hatherill M; Geldenhuys H; Hill AV; Hussey GD; Mahomed H; Hanekom WA; McShane H
J Infect Dis; 2011 Jun; 203(12):1832-43. PubMed ID: 21606542
[TBL] [Abstract][Full Text] [Related]
3. Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.
Tanner R; Kakalacheva K; Miller E; Pathan AA; Chalk R; Sander CR; Scriba T; Tameris M; Hawkridge T; Mahomed H; Hussey G; Hanekom W; Checkley A; McShane H; Fletcher HA
BMC Infect Dis; 2014 Dec; 14():660. PubMed ID: 25466778
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
Whelan KT; Pathan AA; Sander CR; Fletcher HA; Poulton I; Alder NC; Hill AV; McShane H
PLoS One; 2009 Jun; 4(6):e5934. PubMed ID: 19529780
[TBL] [Abstract][Full Text] [Related]
5. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Manjaly Thomas ZR; Satti I; Marshall JL; Harris SA; Lopez Ramon R; Hamidi A; Minhinnick A; Riste M; Stockdale L; Lawrie AM; Vermaak S; Wilkie M; Bettinson H; McShane H
PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
[TBL] [Abstract][Full Text] [Related]
6. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
McShane H; Pathan AA; Sander CR; Keating SM; Gilbert SC; Huygen K; Fletcher HA; Hill AV
Nat Med; 2004 Nov; 10(11):1240-4. PubMed ID: 15502839
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
Satti I; Meyer J; Harris SA; Manjaly Thomas ZR; Griffiths K; Antrobus RD; Rowland R; Ramon RL; Smith M; Sheehan S; Bettinson H; McShane H
Lancet Infect Dis; 2014 Oct; 14(10):939-46. PubMed ID: 25151225
[TBL] [Abstract][Full Text] [Related]
8. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.
Beveridge NE; Price DA; Casazza JP; Pathan AA; Sander CR; Asher TE; Ambrozak DR; Precopio ML; Scheinberg P; Alder NC; Roederer M; Koup RA; Douek DC; Hill AV; McShane H
Eur J Immunol; 2007 Nov; 37(11):3089-100. PubMed ID: 17948267
[TBL] [Abstract][Full Text] [Related]
9. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Wilkie M; Satti I; Minhinnick A; Harris S; Riste M; Ramon RL; Sheehan S; Thomas ZM; Wright D; Stockdale L; Hamidi A; O'Shea MK; Dwivedi K; Behrens HM; Davenne T; Morton J; Vermaak S; Lawrie A; Moss P; McShane H
Vaccine; 2020 Jan; 38(4):779-789. PubMed ID: 31735500
[TBL] [Abstract][Full Text] [Related]
11. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.
Scriba TJ; Tameris M; Mansoor N; Smit E; van der Merwe L; Isaacs F; Keyser A; Moyo S; Brittain N; Lawrie A; Gelderbloem S; Veldsman A; Hatherill M; Hawkridge A; Hill AV; Hussey GD; Mahomed H; McShane H; Hanekom WA
Eur J Immunol; 2010 Jan; 40(1):279-90. PubMed ID: 20017188
[TBL] [Abstract][Full Text] [Related]
12. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
Pathan AA; Minassian AM; Sander CR; Rowland R; Porter DW; Poulton ID; Hill AV; Fletcher HA; McShane H
Vaccine; 2012 Aug; 30(38):5616-24. PubMed ID: 22789508
[TBL] [Abstract][Full Text] [Related]
13. Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
Fletcher HA; Pathan AA; Berthoud TK; Dunachie SJ; Whelan KT; Alder NC; Sander CR; Hill AV; McShane H
Vaccine; 2008 Sep; 26(41):5269-75. PubMed ID: 18682270
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
Tchilian EZ; Desel C; Forbes EK; Bandermann S; Sander CR; Hill AV; McShane H; Kaufmann SH
Infect Immun; 2009 Feb; 77(2):622-31. PubMed ID: 19064635
[TBL] [Abstract][Full Text] [Related]
15. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.
Darrah PA; Bolton DL; Lackner AA; Kaushal D; Aye PP; Mehra S; Blanchard JL; Didier PJ; Roy CJ; Rao SS; Hokey DA; Scanga CA; Sizemore DR; Sadoff JC; Roederer M; Seder RA
J Immunol; 2014 Aug; 193(4):1799-811. PubMed ID: 25024382
[TBL] [Abstract][Full Text] [Related]
16. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
Tameris MD; Hatherill M; Landry BS; Scriba TJ; Snowden MA; Lockhart S; Shea JE; McClain JB; Hussey GD; Hanekom WA; Mahomed H; McShane H;
Lancet; 2013 Mar; 381(9871):1021-8. PubMed ID: 23391465
[TBL] [Abstract][Full Text] [Related]
18. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.
Vordermeier HM; Villarreal-Ramos B; Cockle PJ; McAulay M; Rhodes SG; Thacker T; Gilbert SC; McShane H; Hill AV; Xing Z; Hewinson RG
Infect Immun; 2009 Aug; 77(8):3364-73. PubMed ID: 19487476
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.
Tameris M; Hokey DA; Nduba V; Sacarlal J; Laher F; Kiringa G; Gondo K; Lazarus EM; Gray GE; Nachman S; Mahomed H; Downing K; Abel B; Scriba TJ; McClain JB; Pau MG; Hendriks J; Dheenadhayalan V; Ishmukhamedov S; Luabeya AK; Geldenhuys H; Shepherd B; Blatner G; Cardenas V; Walker R; Hanekom WA; Sadoff J; Douoguih M; Barker L; Hatherill M
Vaccine; 2015 Jun; 33(25):2944-54. PubMed ID: 25936724
[TBL] [Abstract][Full Text] [Related]
20. A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
Sheehan S; Harris SA; Satti I; Hokey DA; Dheenadhayalan V; Stockdale L; Manjaly Thomas ZR; Minhinnick A; Wilkie M; Vermaak S; Meyer J; O'Shea MK; Pau MG; Versteege I; Douoguih M; Hendriks J; Sadoff J; Landry B; Moss P; McShane H
PLoS One; 2015; 10(11):e0141687. PubMed ID: 26529238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
